Innovative drug track warms up, related ETFs attract active capital allocation.

Recently, driven by multiple factors such as policy optimization, industry catalysis, and capital inflow, the innovative drug sector has been performing actively. Institutions believe that with the continuous improvement of the industry fundamentals and the accelerated realization of innovation results, the innovative drug sector is expected to usher in a new round of valuation repair opportunities. Data shows that as of June 30th, several innovative drug-related ETFs have seen net inflows of funds in the past week. Among them, the GF CSI Pharmaceutical Innovation ETF saw an increase of 5.26 billion yuan in funds holdings in the past week, while the GF CSI Hong Kong Innovation Drug ETF and the Guotai CSI Tech Innovation Board Innovation Drug ETF both saw net inflows of over 4 billion yuan. Additionally, the E Fund CSI Pharmaceutical Innovation Industry ETF and the Harvest Fund GuoZhen Hong Kong Stock Connect Innovation Drug ETF also saw fund increases. At the same time, the profitability of the sector continues to manifest. As of July 1st, the Guotai CSI Tech Innovation Board Innovation Drug ETF increased by 16.24% in the past week, the Harvest Fund CSI Tech Innovation Board Innovation Drug ETF increased by 15.96%, and products such as the Fuguo CSI Shanghai-Hong Kong-Shenzhen Innovation Drug Industry ETF saw increases exceeding 10%.